All News

Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.

Research further shows a significant association between patients with psoriasis and an increased incidence of obstructive sleep apnea (OSA).

The prevalence rates of metabolic dysfunction–associated steatohepatitis (MASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are likely underestimated using claims data alone.

Amidst ambiguous international guidelines for first-line treatment of opioid use disorder, a new population-based study sheds light on the benefits of methadone vs buprenorphine/naloxone for holding off treatment discontinuation.

Researchers explored innovative approaches to overcome barriers and drive sustainable biosimilar utilization.

At our recent Institute for Value-Based Medicine® event in Boston, Hari Deshpande, MD, Yale Cancer Center, presented on predictive biomarkers in sarcomas.

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment options, but addressing its limitations is crucial for future success.

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology, and more.

Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.

Two genes were shown to be significantly associated with higher prevalence of myasthenia gravis (MG), a relatively rare autoimmune disease.

Using Mendelian randomization analysis, researchers found evidence that 2 small groups of immunophenotypes are linked to either greater or lesser odds of developing pulmonary arterial hypertension (PAH).

Despite advancements in umbilical cord blood transplants, social determinants of health, such as poverty and public insurance, continue to impact outcomes, underscoring the need for equitable access to lifesaving treatments.

Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring the urgent need for targeted interventions to address these inequities.

Experts discuss pricing, utilization, and health plan strategies to drive biosimilar uptake.

Many talks at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference advocated for the adoption of culturally relevant care, the leveraging of community partnerships, and community engagement to build better trust with patients and improve outcomes.

Two posters compared health care resource utilization (HCRU) and financial burdens of people living with HIV with a non-HIV population and people with HIV who are heavily treated with those have experienced less treatment.

Patients with low-count chronic lymphocytic leukemia phenotype monoclonal B-cell lymphocytosis had a 1.86-fold greater risk of melanoma.

Optune Lua creates tumor-treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 inhibitors or docetaxel to treat metastatic non–small cell lung cancer (NSCLC) that has not responded to platinum-based treatment.

The study showed that having pre-existing leukopenia and more favorable performance status was associated with a higher risk of rash.

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.

Experts reevaluate coverage policies and the financial impact of antiobesity medications based on updated clinical data and key utilization trends.

At CHEST 2024, Cesar Davila-Chapa, MD, University of Nebraska Medical Center, brings awareness to the racial disparities demonstrated in his investigation of idiopathic pulmonary fibrosis (IPF) hospitalizations and outcomes.

The progress made to mitigate the opioid use crisis still pales in comparison with the crucial effort needed to address it, especially in regard to accessing medication.

The phase 2 PICCOLO trial demonstrated that mirvetuximab soravtansine (Elahere; AbbVie) is effective and tolerable in heavily pre-treated patients with folate receptor alpha-positive (FRα+), platinum-sensitive ovarian cancer.

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post-discharge pulmonary rehabilitation (PR), with ineligibility significantly limiting uptake.

Women are still being excluded from cardiovascular research trials, and it has a lasting impact on heart disease treatment for women today.

Full-time caregivers to loved one's with Alzheimer disease or other dementias could earn over $100,000 annually if they were compensated for their time and responsibilities.

Early data from the CDC demonstrates a slight decrease in drug fatalities in children compared with 2022.

Financial toxicity and patient and staff wellness were well explored at the Association of Cancer Care Centers (ACCC) 41st National Oncology Conference, serving as the focal point of multiple posters and presentations.